New hope for GIST: experimental combo targets hard-to-treat tumors
NCT ID NCT07406633
First seen Feb 21, 2026 · Last updated May 07, 2026 · Updated 7 times
Summary
This study tests whether adding an experimental drug (KQB198) to the standard cancer pill imatinib is safe and works better for people with advanced gastrointestinal stromal tumor (GIST). About 46 adults whose cancer has spread and who have not yet received treatment for advanced disease will take the combination. The main goal is to see if tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIST are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
Conditions
Explore the condition pages connected to this study.